Our Clinical Research Unit in Leeds was established in 1986 and we're proud to carry out clinical trials for some of the world's leading pharmaceutical and biotechnology companies.
Every member of our team, including our physicians and nurses, has an important role to play in conducting medical trials. We’re committed to making progress in new treatments for conditions such as diabetes, epilepsy, osteoporosis and Alzheimer's disease. It's our passion and what drives the medical breakthroughs of tomorrow.
Phase I studies, including First-in-Human studies, determine how drugs are absorbed into the body, as well as the amount of time they stay in the body. Safety of the drug and side effects are evaluated at different dose levels. Other studies conducted during Phase I include how drugs interact with other drugs, comparing a generic drug to a name brand drug, and the effect of food on the drug.
These studies help us determine whether a drug shows promising results in treating the condition for which it is being developed. We use small numbers of participants with mild-to-moderate forms of these conditions, for example diabetes, asthma and high blood pressure, but who are otherwise healthy.
These studies involve thousands of participants with the medical condition the drug is being developed to treat. Healthy individuals may participate in Phase III studies for smoking cessation, insomnia, weight loss, etc.
These studies involve further testing in large numbers of individuals after the product is released on the market.